ACE2 and COVID-19: The loss of ACE2-mediated anti-inflammatory, antithrombotic, and anti-fibrotic effects, along with the upregulation of the angiotensin II-AT1 axis, may contribute to the development of the cytokine storm and thrombo-inflammatory state associated with COVID-19 (26).